Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2020, with the announcement issued on June 29, 2020. The filing reports a significant regulatory milestone: the approval of Duvroq (daprodustat) by the Ministry of Health, Labour and Welfare in Japan for the treatment of anaemia due to chronic kidney disease (CKD).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory announcement regarding a specific product approval rather than a financial results report.
Material Changes and Product Details
- Regulatory Approval: GSK received approval for Duvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), in Japan.
- Indication: Treatment of anaemia in adult patients with CKD (stages 3-5), including those on dialysis (hemo- and peritoneal) and those not on dialysis.
- Market Opportunity: The approval targets approximately 3.5 million patients in Japan with anaemia associated with renal disease.
- Commercialization: In Japan, Duvroq will be exclusively distributed by Kyowa Kirin Co., Ltd. (KKC) under a strategic deal announced in 2018. GSK will support scientific engagement.
- Competitive Advantage: Duvroq offers an oral, once-daily dosing option, contrasting with the current standard of care which requires injections.
Guidance, Outlook, and Risks
Outlook and Pipeline
GSK is conducting an ongoing global Phase III programme to support additional regulatory submissions worldwide. Key studies include:
- ASCEND-D: Enrolled approximately 3,000 dialysis-dependent patients; recruitment is complete.
- ASCEND-ND: Will enrol approximately 4,500 non-dialysis-dependent patients; recruitment is ongoing.
- Endpoints: Studies assess non-inferiority to erythropoiesis-stimulating agents (ESAs) regarding major adverse cardiovascular events (MACE) and mean change in haemoglobin.
Risks and Contingencies
The Japanese Prescribing Information highlights serious risks, including:
- Thromboembolism: Serious events such as cerebral infarction, myocardial infarction, and pulmonary embolism may occur, sometimes resulting in death.
- Adverse Reaction Frequency: Thromboembolism occurred in 0.8% of patients in the prescribing information data.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2019 Form 20-F and impacts of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the commercial launch timeline and sales projections for Duvroq in Japan with Kyowa Kirin.
- Monitor the results of the global ASCEND-D and ASCEND-ND Phase III studies for cardiovascular safety and efficacy data.
- Review the specific safety profile and post-marketing surveillance data regarding thromboembolic events.
- Assess the impact of the COVID-19 pandemic on the global clinical trial recruitment and regulatory timelines.
- Confirm the financial terms and royalty structures of the commercialization agreement with Kyowa Kirin.